Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma
Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to
HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell
transplantation in patients with relapsed/refractory lymphoma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society